17Oct 2017
MediWound Ltd. (Nasdaq: MDWD) has signed an agreement with Holy Stone Healthcare Co., Ltd. on October 16, 2017, granting Holy Stone Healthcare the exclusive distribution rights of NexoBrid® in Taiwan.
read more
30Jun 2017
Holy Stone Healthcare Co., Ltd., together with representatives of MDT Int’l S.A., attended 2017 BIO International Convention in San Diego, USA. on June 19-22.
read more
31May 2017
A research report of IBD98-M for inflammatory bowel disease from Holy Stone Healthcare, is published on 《Molecules》
read more

Vision & Mission

We are committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients worldwide. Our mission is to create innovative therapeutic products based on hyaluronic acid using our know-how and experience to address unmet clinical needs with superior tolerability and efficacy.


We are focused on development of new drugs and medical devices, especially hyaluronic acid related therapeutic products.